As Senior Vice President of Program and Alliance Management, Dr. Schostack played a vital role in advancing TB drug development and forging critical partnerships
After more than 40 years working in pharmaceutical development, Dr. Kathy Schostack is retiring from her role as Senior Vice President, Program and Alliance Management at TB Alliance at the end of August 2025. During her tenure at TB Alliance, Dr. Schostack brought her extensive expertise to the fight against tuberculosis (TB), helping to drive the research and development of new and improved TB treatments. Her leadership has been vital to the organization’s mission to bring life-saving TB therapies to those who need them most.
Kathy’s career spans 40+ years in pharmaceutical development, from early-stage research through late-stage clinical trials, regulatory approvals, product launches, and post-approval management. Prior to joining TB Alliance, she held leadership positions at Hoffmann-La Roche and Bayer HealthCare, where she led efforts in analytical research and development, regulatory affairs, and project management across various therapeutic areas – with a particular focus on oncology. She earned her Ph.D. and M.S. degrees in Chemistry from Stevens Institute of Technology and a B.S. from Penn State University. This strong scientific and project management background laid the groundwork for her impactful contributions to TB drug development.
At TB Alliance, Kathy applied rigorous project management principles to drive critical programs to successful completion. She also spearheaded alliances with key partners to ensure productive collaborations. During Kathy’s tenure, she led several major initiatives for TB Alliance. Notably, the organization achieved the approval of pretomanid in 2019 as part of a groundbreaking three-drug regimen (BPaL) for highly drug-resistant TB. This was a historic accomplishment: pretomanid is only the third new anti-TB drug approved by the U.S. FDA in more than 40 years, and the first to be developed and registered by a not-for-profit organization. Efforts like this underscore the impact of Kathy’s work in guiding complex development programs and fostering partnerships that bring novel TB treatments to people worldwide.
“Working with TB Alliance has been one of the most rewarding chapters of my career,” said Kathy, reflecting on her time at TB Alliance. “I am incredibly proud of what we have accomplished together in the fight against TB, and I have been continually inspired by the dedication of our team and partners. I am grateful for the opportunity to contribute to a mission that saves lives and I will continue to cheer on TB Alliance’s efforts as they work to develop new treatments to improve the lives of TB patients and their families.” Though Dr. Schostack is retiring from her official role, her impact on TB Alliance and the global TB community will endure. TB Alliance congratulates Kathy Schostack on her retirement and extends its heartfelt gratitude for her years of leadership and service.